NEW YORK – Researchers at Yale and Rutgers universities have developed a fast method to detect rare disease-causing point mutations directly from blood. Using a novel amplification technology coupled ...

NEW YORK – Qiagen announced on Wednesday that it has launched a third-party partnering program for its clinical digital PCR platform and signed an agreement with the program's inaugural partner, South ...

NEW YORK – The US Department of Justice said Wednesday that a Chicago lab owner has been sentenced to seven years in prison for his role in a COVID-19 testing fraud. During 2021 and 2022, lab owner ...

NEW YORK – In a letter to customers on Wednesday, Bio-Rad Laboratories announced that it has decided against implementing a tariff surcharge that the company on May 21 said it was considering for at ...

Adding the firm's multi-cancer early detection test to standard-of-care screening demonstrated substantially greater additional cancer detection than in Pathfinder.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.